Epigral Share Price Target 2026 Analyst Forecast Bull and Bear Case
- July 3, 2026
- Posted by: Kunal Singla
- Category: News
Epigral CMP Rs 1,063. 52W High Rs 2,114 | Low Rs 806. Mcap Rs 4,687 Cr. 12M Target Rs 1,490. PE: 14.12.
The Epigral share price target stands at Rs 1,490 for 2026, implying approximately 40% upside from the current market price of Rs 1,063. The stock trades at a price-to-earnings ratio of 14.12x, reflecting attractive value versus sector peers, with a market capitalisation of Rs 4,687 Cr. Investors tracking the specialty chemicals segment are closely watching Epigral as an emerging opportunity given its 52-week range of Rs 806 to Rs 2,114. This analysis covers the bull case, bear case, and key catalysts that will define the Epigral share price target trajectory through 2026.
Click Here – Get Free Investment Predictions
Epigral Company Overview and Key Metrics
| Epigral | Details |
|---|---|
| NSE Symbol | EPIGRAL |
| Sector | Specialty Chemicals |
| CMP (Rs) | 1,063 |
| 52W High (Rs) | 2,114 |
| 52W Low (Rs) | 806 |
| Market Cap (Rs Cr) | 4,687 Cr |
| P/E Ratio | 14.12 |
| 12M Target (Rs) | 1,490 |
| Bull Case (Rs) | 1,715 |
| Bear Case (Rs) | 1,190 |
Epigral is a specialty chemicals company listed on the National Stock Exchange (NSE: EPIGRAL). With a market capitalisation of Rs 4,687 Cr, the company occupies a defined position in the Indian specialty chemicals landscape. The stock has traded in a wide range over the past 12 months, touching a high of Rs 2,114 and a low of Rs 806, before arriving at its current level of Rs 1,063. Uniresearch analysts project a 12-month Epigral share price target of Rs 1,490, with a bull case of Rs 1,715 and a bear case of Rs 1,190.
Why Is the Epigral share price target Set at Rs 1,490 for 2026
FY27 Earnings Delivery and Revenue Acceleration
The Epigral share price target of Rs 1,490 is anchored in expectations of FY27 earnings delivery. At a P/E of 14.12x on trailing earnings, the stock is attractively valued. Consistent revenue growth and margin improvement in coming quarters can re-rate the stock towards the Rs 1,490 target.
China Plus One Beneficiary
Global chemical companies are actively diversifying supply chains away from China, creating significant opportunity for Indian chemical manufacturers. The shift is accelerating as buyers seek supply security and quality compliance from alternative vendors.
Domestic Agrochemical Demand Cycle
India’s agrochemical market benefits from monsoon-driven crop protection demand cycles. A normal monsoon with adequate rainfall can boost pesticide, herbicide, and fertiliser volumes significantly in the second half of the fiscal year.
RBI Rate Cut Cycle and Lower Cost of Capital
The Reserve Bank of India has shifted to an accommodative monetary policy stance, with rate cuts reducing borrowing costs across the economy. For Epigral, lower interest rates translate to reduced finance costs and potentially higher consumer demand in its end markets, creating a favourable backdrop for the Epigral share price target to materialise by year-end.
Union Budget 2026 and Policy Tailwinds
The Union Budget 2026-27 has maintained strong capex allocation of Rs 11 lakh crore for infrastructure, directly benefiting sectors including specialty chemicals. Tax rationalisation and sector-specific policy support create a constructive policy environment that supports the Epigral share price target thesis through improved demand visibility.
Epigral Share Price Target Short Term, 12 Month and Long Term
Short Term Epigral Share Price Target: 3 to 6 Months
In the near term, the Epigral share price target for the next 3 to 6 months is pegged at Rs 1,150, contingent on Q1 FY27 earnings meeting expectations and sustained buying interest in the specialty chemicals segment. Technically, the stock needs to hold the Rs 846-887 zone for this short-term target to remain valid.
12 Month Epigral Share Price Target 2026
Our 12-month Epigral share price target is Rs 1,490. This target is based on the Uniresearch fundamental estimate, which factors in FY27 revenue growth, margin normalisation, and sector re-rating potential. The Rs 1,490 level represents approximately 40% upside from the current price of Rs 1,063.
Long Term Epigral Share Price Target: FY27 to FY28
Over a 2 to 3 year horizon, the long-term Epigral share price target is estimated between Rs 1,713 and Rs 2,012, assuming continued compounding in earnings, potential capacity expansions, and improved market positioning. Investors with a multi-year holding perspective may find the current CMP of Rs 1,063 an attractive accumulation level.
Bull Case and Bear Case for Epigral Share Price Target
Bull Case: Rs 1,715
In the bull case scenario, Epigral delivers above-estimate earnings growth driven by strong demand, margin expansion, and new business wins. If these catalysts materialise simultaneously, the Epigral share price target could reach Rs 1,715, implying approximately 61% upside from the current market price.
Bear Case: Rs 1,190
The bear case of Rs 1,190 assumes earnings disappointment, sector-level de-rating, or broader market selloff driven by FII outflows. In this scenario, Epigral could re-test support levels closer to its 52-week low of Rs 806, representing a downside risk investors should monitor.
| Scenario | Target Price (Rs) | Upside/Downside from CMP | Key Assumption |
|---|---|---|---|
| Bull Case | 1,715 | 61% | Strong earnings growth, sector re-rating |
| Base Case | 1,490 | 40% | Steady earnings, margin improvement |
| Bear Case | 1,190 | 12% | Earnings miss, macro headwinds |
Key Risks to the Epigral Share Price Target 2026
Macro Headwind from Global Slowdown and US Tariff Policy
A sharper-than-expected global slowdown or escalation in US-China trade tensions could dampen demand across sectors. Epigral faces indirect risk if its customers or supply chain partners are impacted by slower global growth, as this could translate to lower order volumes or pricing pressure.
Valuation Risk and Earnings Miss Scenario
If Epigral reports quarterly earnings below analyst estimates or provides weak forward guidance, the stock could see significant de-rating. Elevated valuations in some segments leave limited margin for error, making execution risk a critical near-term concern.
Competitive Pressure in the Specialty Chemicals Segment
The specialty chemicals space in India is increasingly competitive with both domestic players and global companies vying for market share. Price competition, product commoditisation, or loss of key client contracts could pressure Epigral’s revenue trajectory.
FII Selling and Broader Market Volatility
Foreign Institutional Investor selling in Indian equities has historically led to broad-based price corrections even in fundamentally sound companies. Epigral’s share price could face near-term pressure if FII sentiment turns risk-off due to global monetary policy changes.
How to Invest in Epigral Stock
Step 1: Research and Fundamental Analysis. Before investing, thoroughly review Epigral’s quarterly results, annual report, and management commentary. Focus on revenue growth trajectory, operating margin trends, and debt levels to assess whether the Epigral share price target of Rs 1,490 is achievable.
Step 2: Use Stock Screeners for Live Data.
Check Epigral Live Data on Univest Screener
Monitor key metrics including P/E, return on equity, and promoter holding changes. These ratios can confirm or challenge the Epigral share price target thesis in real time.
Step 3: Define Your Entry Zone. The current CMP of Rs 1,063 is within the identified accumulation zone based on the 52-week low of Rs 806 and the Uniresearch target of Rs 1,490. Consider entering in tranches to average your cost over market fluctuations.
Step 4: Set Stop Loss and Risk Management Levels. Always define a stop-loss level before investing. A prudent stop-loss for Epigral based on the current technical setup would be in the Rs 936 to Rs 978 range. Never risk more than 2-5% of your portfolio in any single position.
Step 5: Open a Zero-Brokerage Demat Account. To invest in Epigral at zero brokerage, open your demat account with Univest, which combines SEBI-registered research with integrated trading. This allows you to act on the Epigral share price target analysis without incurring unnecessary transaction costs.
Download the Univest iOS App or Univest Android App to track Epigral live price and get daily stock recommendations.
Conclusion
The Epigral share price target for 2026 is Rs 1,490, with a bull case of Rs 1,715 and a bear case of Rs 1,190, based on Uniresearch estimates as of 29 June 2026. At a CMP of Rs 1,063 with a 52-week range of Rs 806 to Rs 2,114, Epigral presents a risk-reward opportunity that warrants monitoring. Investors should review Q1 FY27 results, track management commentary on guidance, and consult a SEBI-registered advisor before making investment decisions. The Epigral share price target outlined here is for educational purposes only.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Epigral Share Price Target 2026
What is the Epigral share price target for 2026?
Ans. The Epigral share price target for 2026, as per Uniresearch estimate, is Rs 1,490. This implies approximately 40% upside from the current market price of Rs 1,063.
Is Epigral a good stock to buy right now?
Ans. Whether Epigral is a good buy depends on your investment horizon, risk appetite, and portfolio allocation. The Uniresearch Epigral share price target of Rs 1,490 implies meaningful upside, but investors must assess company fundamentals and market conditions before investing.
What is Epigral’s 52-week high and low?
Ans. Epigral’s 52-week high is Rs 2,114 and the 52-week low is Rs 806, as of 29 June 2026. The current price of Rs 1,063 represents a 32% gain from the 52-week low.
What is the market cap of Epigral?
Ans. The market capitalisation of Epigral is approximately Rs 4,687 Cr, as of 29 June 2026.
What are the key risks to the Epigral share price target?
Ans. Key risks to the Epigral share price target of Rs 1,490 include earnings disappointment, global macro headwinds, FII selling pressure, and competitive intensity in the specialty chemicals sector. Any of these factors could delay or reduce the target realisation.
What is the bull case target for Epigral in 2026?
Ans. In the bull case scenario, the Epigral share price target could reach Rs 1,715, implying approximately 61% upside from the current level. This assumes stronger-than-expected earnings growth and sector re-rating.
Where can I track Epigral share price live?
Ans. You can track Epigral (NSE: EPIGRAL) live price, charts, and fundamental data on the Univest app or screener. The Univest platform provides real-time price data, analyst research, and portfolio tracking in one place.
How do I invest in Epigral stock?
Ans. To invest in Epigral, open a demat account with a SEBI-registered broker like Univest, which offers zero brokerage and integrated research. Search for the ticker EPIGRAL on NSE, review fundamentals using the Univest Screener, and invest based on your financial goals and risk profile.
